[August 11, 2016]

Global Glioblastoma Multiforme Market Study 2016: Prognosis of Patients with GBM Remains Poor as Drug Developers Turn to Immunotherapies - Research and Markets

Research and Markets has announced the addition of the "Glioblastoma Multiforme" report to their offering.

The prognosis of patients with GBM remains poor as drug developers turn to immunotherapies to provide more effective options.

This report addresses the following questions:

- What is the current standard of care for patients with GBM in each treatment setting, and how effective are these options?

- What are the major challenges facing drug developers in GBM?

- How do the various PD-1 pathway inhibitors, gene therapies, and vaccines currently in development for GBM compare in terms of safety and efficacy?

- What patient segmentations are most relevant in the treatment of GBM?

Key Topics Covere:

TREATMENT: GLIOBLASTOMA MULTIFORME

- Disease Definition and Diagnosis

- Patient Segmentation

- Country Treatment Trees

- Current Treatment Options

- Prescribing Trends

- Unmet Needs

EPIDEMIOLOGY: GLIOBLASTOMA MULTIFORME

- Disease Definition

- Global Variation

- Risk Factors

- Sources and Methodology

- Forecast

- Epidemiologist Insight

- Strengths and Limitations,

- Bibliography

MARKETED DRUGS: GLIOBLASTOMA MULTIFORME

- Product profile: Avastin

- Product profile: Temodar

PIPELINE: GLIOBLASTOMA MULTIFORME

- Clinical Pipeline Overview

- Target (News - Alert) Product Profile

- Clinical Trial Design

- Recently Discontinued Drugs

- Product profile (late stage): DCVax-L

- Product profile (late stage): ICT-1

- Product profile (late stage): Opdivo

- Product profile (late stage): Toca 511/FC

- Product profile (late stage): VB-111

For more information visit http://www.researchandmarkets.com/research/bfvg7h/glioblastoma

View source version on businesswire.com: http://www.businesswire.com/news/home/20160811005357/en/

[ Back To TMCnet.com's Homepage ]